In what can only be viewed as a major setback for those advocating pre-exposure prophylaxis--giving anti-retroviral treatment to people who are HIV negative but determined to be at high risk of infection, aka Prep--a major clinical trial on the efficacy of Prep has been halted because it was deemed unlikely to achieve the desired result.

This is great news for activists, like me, who oppose the FDA’s potential approval of an indication for Gilead’s Truvada for this purpose.  The halted trial was exploring Prep’s potential use as a prevention strategy for HIV negative women.

This is big news and there is sure to be lots of commentary on it over the next few weeks.  Read more about it here.

This is